



Attorney Docket No. 405-232DV

*code*  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Amalfitano et al.

U.S. Patent No.: 6,797,265 *B2*

Application Serial No.: 09/972,794

Issued: September 28, 2004

Filed: October 5, 2001

For: *Deleted Adenovirus Vectors and Methods of Making and Administering the Same*

Date: November 23, 2004

Commissioner for Patents

Attn: Certificate of Correction Branch

P.O. Box 1450

Alexandria, VA 22313-1450

**Certificate**

DEC 01 2004

**of Correction**

**REQUEST FOR ENTRY OF CERTIFICATE OF CORRECTION UNDER  
35 U.S.C §254 AND 37 C.F.R. §1.322**

Sir:

The Assignee of record for the above-referenced patent hereby requests, pursuant to 35 U.S.C §254 and 37 C.F.R. §1.322, that a Certificate of Correction be issued. This request is made in order to correct the mistakes incurred through the fault of the U.S. Patent and Trademark Office. No fee is believed due. However, the Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

The mistakes appearing in the patent are set forth with corrections on the Certificate of Correction enclosed herewith, with an additional copy thereof and a return post card.

Respectfully submitted,

Karen A. Magri

Registration No. 41,965

Myers Bigel Sibley & Sajovec, P.A.

P. O. Box 37428

Raleigh, North Carolina 27627

Telephone: (919) 854-1400

Facsimile: (919) 854-1401

Customer No. 20792

**Certificate of Mailing under 37 CFR 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Attn: Certificate of Correction Branch, P.O. Box 1450, Alexandria, VA 22313-1450 on November 23, 2004.

Monica L. Croom

DEC 03 2004

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,797,265 *B2*  
DATED : September 28, 2004  
INVENTOR(S) : Amalfitano et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Specification:

Column 29, lines 35-36 should read -- Construction of [E1-, Δpol, E3-] and [E1-, Δpol, ΔpTP, E3-] Ad Vectors --

Column 31, line 60 should read -- mm Tris·Cl (pH 8.0), sonicated, and the virus purified by two --

In the Claims:

Column 57, claim 4 should read -- 4. The adenovirus vector of Claim 1, wherein said adenovirus genome comprises a 100K region comprising a deletion at about nucleotides 24,990 to 25,687 of the adenovirus serotype 5 genome or a corresponding region of the genome of adenoviruses of other serotypes. --

Column 57, claim 5 should read -- 5. The adenovirus vector of Claim 4, wherein said adenovirus vector is disclosed herein as [E1<sup>-</sup>, 100K<sup>-</sup>]Ad. --

Column 58, claim 18 should read -- 18. The adenovirus vector of Claim 17, wherein said protein or peptide is associated with a lysosomal storage disease.

Column 59, claim 35 should read -- 35. An isolated mammalian cell comprising an isolated DNA comprising a nucleotide sequence encoding an adenovirus 100K protein, wherein said isolated DNA is stably integrated into the genome of said cell, and wherein said cell can propagate an adenovirus genome that essentially lacks expression of a functional adenovirus 100K protein. --

Column 60, claim 40 should read -- 40. The cell of Claim 35, further comprising a recombinant adenovirus genome, wherein said adenovirus genome lacks a coding sequence for a functional adenovirus 100K protein. --

Column 60, claim 52 should read -- 52. The method of Claim 51, wherein the adenovirus vector is disclosed herein as [E1<sup>-</sup>, 100K<sup>-</sup>]Ad. --

Column 61, claim 62 should read -- 62. The method of Claim 60, wherein the helper adenovirus is disclosed herein as [E1<sup>-</sup>, 100K<sup>-</sup>]Ad. --

MAILING ADDRESS OF SENDER:  
Myers, Bigel, Sibley & Sajovec  
P.O. Box 37428  
Raleigh, NC 27627

PATENT NO. 6,797,265  
No. of additional copies: \_\_\_\_\_



This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DEC 03 2004

Attorney Docket No. 5405-23210V



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Amalfitano et al.

Application Serial No.: 09/972,794

Filed: October 5, 2001

For: *Deleted Adenovirus Vectors and Methods of Making and Administering the Same*

U.S. Patent No.: 6,797,265 B2

Issued: September 28, 2004

Date: November 23, 2004

Commissioner for Patents

Attn: Certificate of Correction Branch

P.O. Box 1450

Alexandria, VA 22313-1450

**REQUEST FOR ENTRY OF CERTIFICATE OF CORRECTION UNDER  
35 U.S.C §254 AND 37 C.F.R. §1.322**

Sir:

The Assignee of record for the above-referenced patent hereby requests, pursuant to 35 U.S.C §254 and 37 C.F.R. §1.322, that a Certificate of Correction be issued. This request is made in order to correct the mistakes incurred through the fault of the U.S. Patent and Trademark Office. No fee is believed due. However, the Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

The mistakes appearing in the patent are set forth with corrections on the Certificate of Correction enclosed herewith, with an additional copy thereof and a return post card.

Respectfully submitted,

Karen A. Magri

Registration No. 41,965

Myers Bigel Sibley & Sajovec, P.A.

P. O. Box 37428

Raleigh, North Carolina 27627

Telephone: (919) 854-1400

Facsimile: (919) 854-1401

Customer No. 20792

**Certificate of Mailing under 37 CFR 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Attn: Certificate of Correction Branch, P.O. Box 1450, Alexandria, VA 22313-1450 on November 23, 2004.

Monica L. Croom

DEC 03 2004

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,797,265 *B2*  
DATED : September 28, 2004  
INVENTOR(S) : Amalfitano et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Specification:

Column 29, lines 35-36 should read -- Construction of [E1-, Δpol, E3-] and [E1-, Δpol, ΔpTP, E3-] Ad Vectors --

Column 31, line 60 should read -- mm Tris·Cl (pH 8.0), sonicated, and the virus purified by two --

In the Claims:

Column 57, claim 4 should read -- 4. The adenovirus vector of Claim 1, wherein said adenovirus genome comprises a 100K region comprising a deletion at about nucleotides 24,990 to 25,687 of the adenovirus serotype 5 genome or a corresponding region of the genome of adenoviruses of other serotypes. --

Column 57, claim 5 should read -- 5. The adenovirus vector of Claim 4, wherein said adenovirus vector is disclosed herein as [E1<sup>-</sup>, 100K<sup>-</sup>]Ad. --

Column 58, claim 18 should read -- 18. The adenovirus vector of Claim 17, wherein said protein or peptide is associated with a lysosomal storage disease.

Column 59, claim 35 should read -- 35. An isolated mammalian cell comprising an isolated DNA comprising a nucleotide sequence encoding an adenovirus 100K protein, wherein said isolated DNA is stably integrated into the genome of said cell, and wherein said cell can propagate an adenovirus genome that essentially lacks expression of a functional adenovirus 100K protein. --

Column 60, claim 40 should read -- 40. The cell of Claim 35, further comprising a recombinant adenovirus genome, wherein said adenovirus genome lacks a coding sequence for a functional adenovirus 100K protein. --

Column 60, claim 52 should read -- 52. The method of Claim 51, wherein the adenovirus vector is disclosed herein as [E1<sup>-</sup>, 100K<sup>-</sup>]Ad. --

Column 61, claim 62 should read -- 62. The method of Claim 60, wherein the helper adenovirus is disclosed herein as [E1<sup>-</sup>, 100K<sup>-</sup>]Ad. --

MAILING ADDRESS OF SENDER:  
Myers, Bigel, Sibley & Sajovec  
P.O. Box 37428  
Raleigh, NC 27627

PATENT NO. 6,797,265  
No. of additional copies: \_\_\_\_\_



This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DEC 03 2004